1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, A8
NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States
Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Shareholders Approve Amendment to 2019 Equity Incentive Plan
Announces First Quarter 2026 Financial Results and Provides Corporate Update
Financial Results, Press Release
CARDAMYST™: First FDA-Approved, Self-Administered Treatment for PSVT
Other Events
Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency
Q2
Q1
FY 2025
Q3
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload